Posts Tagged: breast oncology
Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer ft. Dr. Gregory Vidal

In a recent OncLive Peer Exchange, Dr. Gregory Vidal partnered with a panel of breast oncology experts to discuss the standard-of-care treatment approaches for early-stage HR-positive/HER2-negative breast cancer. Topics include: – Evolution of HER2-negative management – Updates in HR-positive treatment – Importance of genetic testing – Utilization of endocrine therapy – BRCA mutations and… Read more »
Meet Dr. Michael Berry

MEET DR. MICHAEL BERRY, Director of our Margaret West Comprehensive Breast Center To know him is to absolutely love him! He is a personable, knowledgable, and compassionate breast surgeon practicing at our Germantown campus. Margaret West Comprehensive Breast Center offers a full suite of breast health services to women from annual mammograms to on-site biopsies, MRIs, ultrasounds,… Read more »
Dr. Lee Schwartzberg on HER2– HR+ Breast Cancer: Tesetaxel & Capecitabine

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01)…. Read more »